Jack W. Callicutt net worth and biography

Jack Callicutt Biography and Net Worth

Chief Financial Officer of Galectin Therapeutics

Mr. Callicutt became our CFO in 2013 and has over 32 years of public and private company experience including more than a decade of audit, tax and SEC registrant experience with a major accounting firm. Prior to joining Galectin, he was chief financial officer for REACH Health, Inc., a telemedicine firm. Previous positions include chief financial officer of Vystar Corporation, a public medical device company whose latex products are devoid of antigenic proteins, where he led all areas of financial reporting, accounting, treasury, risk management. Previous experiences also include chief financial officer roles at private companies including IVOX and Tikvah Therapeutics, and at Corautus Genetics, a publicly-traded biopharmaceutical company. Mr. Callicutt is a certified public accountant and graduated cum laude with a B.B.A. degree in accounting and computer science from Delta State University.

What is Jack W. Callicutt's net worth?: The estimated net worth of Jack W. Callicutt is at least $33.12 thousand as of January 6th, 2026. Mr. Callicutt owns 7,614 shares of Galectin Therapeutics stock worth more than $33,121 as of July 1st. This net worth approximation does not reflect any other investments that Mr. Callicutt may own. Learn More about Jack W. Callicutt's net worth.
How do I contact Jack W. Callicutt?: The corporate mailing address for Mr. Callicutt and other Galectin Therapeutics executives is 4960 PEACHTREE INDUSTRIAL BLVD. SUITE 240, NORCROSS GA, 30071. Galectin Therapeutics can also be reached via phone at (678) 620-3186 and via email at [email protected]. Learn More on Jack W. Callicutt's contact information.
Has Jack W. Callicutt been buying or selling shares of Galectin Therapeutics?: Jack W. Callicutt has not been actively trading shares of Galectin Therapeutics during the last ninety days. Most recently, Jack W. Callicutt sold 20,354 shares of the business's stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $3.67, for a transaction totalling $74,699.18. Following the completion of the sale, the chief financial officer now directly owns 7,614 shares of the company's stock, valued at $27,943.38. Learn More on Jack W. Callicutt's trading history.
Who are Galectin Therapeutics' active insiders?: Galectin Therapeutics' insider roster includes Jack Callicutt (Chief Financial Officer), Kevin Freeman (Director), Elissa Schwartz (Director), Harold Shlevin (Director), and Richard Zordani, Jr. (Director). Learn More on Galectin Therapeutics' active insiders.
Are insiders buying or selling shares of Galectin Therapeutics?: During the last twelve months, Galectin Therapeutics insiders bought shares 3 times. They purchased a total of 2,000 shares worth more than $6,341.00. During the last twelve months, insiders at the sold shares 32 times. They sold a total of 944,585 shares worth more than $5,050,478.51. The most recent insider tranaction occured on June, 29th when Director Harold H Shlevin sold 22,268 shares worth more than $112,230.72. Insiders at Galectin Therapeutics own 52.6% of the company. Learn More about insider trades at Galectin Therapeutics.
Information on this page was last updated on 6/29/2026.

Jack W. Callicutt Insider Trading History at Galectin Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/6/2026	Sell	20,354	$3.67	$74,699.18	7,614
1/5/2026	Sell	25,732	$3.90	$100,354.80	27,968
1/2/2026	Sell	13,914	$4.20	$58,438.80	53,700
11/4/2025	Sell	28,629	$6.07	$173,778.03	7,614
11/3/2025	Sell	3,810	$6.01	$22,898.10	7,614
9/12/2025	Sell	8,706	$6.44	$56,066.64	7,614
12/23/2024	Sell	40,000	$0.89	$35,600.00	7,614
11/17/2022	Buy	4,000	$1.32	$5,280.00	7,614
5/31/2019	Buy	2,354	$4.28	$10,075.12	3,614
6/20/2018	Sell	226,000	$8.61	$1,945,860.00	103,993
6/11/2018	Sell	120,000	$5.85	$702,000.00	101,260
6/8/2018	Sell	100,000	$5.75	$575,000.00	101,260
5/31/2018	Sell	46,651	$5.00	$233,255.00	47,911
4/4/2018	Sell	3,349	$5.00	$16,745.00	4,609
8/14/2014	Buy	1,000	$4.55	$4,550.00

Jack W. Callicutt Buying and Selling Activity at Galectin Therapeutics

Galectin Therapeutics Company Overview

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Today's Range

Now: $4.44

$4.28

$4.64

50 Day Range

MA: $2.65

$2.08

$4.97

2 Week Range

Now: $4.44

$2.03

$7.13

Volume

285,628 shs

Average Volume

459,155 shs

Market Capitalization

$292.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.47